Two low-dose OKT3 induction regimens following renal transplantation - Clinical experience at a single center

Clinical Transplantation

Volumn 12, Issue 4, 1998, Pages 343-347

  Oh, Henry K ^a,b   Provenzano, Robert ^a   Tayeb, Jakaku ^a   Satmary, Nancy ^a   Jones, Bruce ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b Transplant Specialty Center   (United States)

Author keywords

Immunosuppression; Kidney transplantation; Muromonab CD3; OKT3

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; OKT 3; PREDNISONE; STEROID;

ADULT; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG COST; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEADACHE; HEART INFARCTION; HERPES; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THRUSH; TREATMENT OUTCOME;

ADULT; CANDIDIASIS, ORAL; CYTOKINES; DRUG COSTS; EVALUATION STUDIES; FEES, PHARMACEUTICAL; FEMALE; FEVER; GRAFT REJECTION; HEADACHE; HERPES SIMPLEX; HOSPITALIZATION; HUMANS; HYPOTENSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MIDDLE AGED; MUROMONAB-CD3; PREMEDICATION; TIME FACTORS;

EID: 0031779374     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. COSIMI AB, BURTON RC, COLVIN RB et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981: 32: 535
2. EVANS RW, MANNINEN DL, DONG FB et al. Immuno-suppressive therapy as a determinant of transplantation outcomes. Transplantation 1993: 55: 1297.
3. ABRAMOWICZ D, GOLDMAN M, DE PAUW L, VANHER-WEGHEM JL, KINNAERT P, VEREERSTRAETEN P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 1992: 54: 433.
4. NORMAN DJ, KAHANA L, STUART FP JR et al A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993: 55: 44.
5. OPELZ G, FOR THE COLLABORATIVE TRANSPLANT STUDY. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995: 60: 1220.
6. NORMAN DJ, KIMBALL JA, BENNETT WM et al. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant Int 1994: 7: 356.
7. ABRAMOWICZ D, GOLDMAN M. OKT3 for induction of immunosuppression in renal transplantation. Clin Transplant 1993: 7: 382.
8. PARLEVLIET KJ, TEN BERGE RJM, RAASVELD MHM, SURACHNO J, WILMINK JM, SCHELLEKENS PTHA. Low-dose OKT3 induction therapy following renal transplantation: a controlled study. Nephrol Dial Transplant 1994: 9: 698.
9. ALLOWAY R, KOTB M, HATHAWAY DK, GABER LW, VERA SR, GABER AO. Randomized double-blind study of standard versus low-dose OKT3 induction therapy in renal allograft recipients. Am J Kidney Dis 1993: 22: 36.
10. OH HK. Use of low-dose OKT3 as induction immunosuppression therapy. Presented at the 11th Annual Meeting of the American Society of Transplant Physicians. May 1992, Chicago, IL.
11. CECKA JM, TERASAKI PI. The UNOS Scientific Renal Transplant Registry. In: TERASAKI PI, CECKA JM, eds. Clinical Transplants 1994. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1995.
12. KREIS H. Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transplant 1993: 7: 431.
13. ALLOWAY R, KOTB M, HATHAWAY D, OHMAN M, STRAIN S, GABER AO. The pharmacokinetic profile of standard and low-dose OKT3 induction immunosuppression in renal transplant recipients. Transplantation 1994: 58: 249.
14. NORMAN DJ, KIMBALL JA, BARRY JM. Cytokine-release syndrome: differences between high and low doses of OKT3. Transplant Proc 1993: 25 (Suppl 1): 35
15. ALONSO-PULPON L, SERRANO-FIZ S, RUBIO JA et al. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation. J Heart Lung Transplant 1995: 14: 136.
16. BROWN M, KORB S, LIGHT JA, LIGHT T, JONSSON J, AQUINO A. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects. Transplant Proc 1993: 25: 553.